Posted by Michael Wonder on 11 May 2026
Zai Lab receives US FDA fast track designation for zocilurtatug pelitecan (Zoci), a DLL3 targeting ADC, for treatment of extrapulmonary neuroendocrine carcinomas
11 May 2026 - Zai Lab today announced the US FDA has granted fast track designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company’s potential first in class Delta-like ligand 3 targeting antibody drug conjugate, for the treatment of extrapulmonary neuroendocrine carcinomas following progression after standard first-line therapy.
Zoci targets delta-like ligand 3, a validated therapeutic target for small cell lung cancer that is overexpressed in many neuroendocrine carcinomas and is generally associated with poor clinical outcomes.
